Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery with rational selection and design, has appointed Bharat Reddy, Ph.D., as its new Chief Business Officer.

Reddy will take the lead on business development activities, bringing more than a decade of experience in corporate development and strategy within the life sciences sector to the role.

“We are thrilled to have Bharat join Magnet during this period of growth for our team and pipeline,” said Brian Safina, Ph.D., CEO of Magnet Biomedicine. “His deep transactional expertise and experience forging strategic biopharma partnerships will be instrumental as we continue to advance our differentiated molecular glue portfolio.”

Experience

Prior to joining Magnet, Reddy was Chief Business Officer at Rectify Pharmaceuticals. He was also formerly Vice President, Strategy and Business Development at Kelonia Therapeutics, where he developed and executed a business strategy and fostered a multi-year collaboration and licensing agreement with Astellas Pharmaceuticals. Earlier in his career, he served as Head of Business Development at Catamaran Bio and as Director, Business Development at bluebird bio. He began his career as a life sciences strategy consultant at ClearView Healthcare Partners.

Reddy holds a B.A. in Biology and Anthropology from Bowdoin College and a Ph.D. from the Department of Biological Sciences at Columbia University.

“Magnet is expanding therapeutic possibilities with our molecular glue inhibitors,” Reddy remarked. “The company’s platform is uniquely positioned to harness the vast potential of molecular glues to bring novel, oral therapies to patients. I look forward to working with the team to identify strategic opportunities that will help us deliver a new generation of small molecule therapeutics that address historically challenging targets and unlock treatment options for diseases with substantial unmet needs.”